MAST CELLS INDUCE MYELOMA PLASMA CELLS? PROLIFERATION
(Abstract release date: 05/19/16)
EHA Library. Tsirakis G. 06/09/16; 134848; PB1948
Dr. Georgios Tsirakis
Contributions
Contributions
Abstract
Abstract: PB1948
Type: Publication Only
Background
Mast cells (MCs) are inflammatory cells that participate actively in multiple myeloma (MM) progression. They mainly enhance angiogenesis through production of various pro-angiogenic molecules, whereas they may also participate per se in the vascular plexus.
Aims
The aim of the study is to explore whether MCs participate in other aspects of MM progression, such as proliferation of plasma cells.
Methods
We studied 57 newly diagnosed patients with active MM, 26 of them in at least partial remission after receiving bortezomib-containing regimens, and 20 age and sex-matched healthy controls. We studied in bone marrow MCs density (MCD) and plasma cells’ proliferation rate (using immunohistochemical expression of tryptase and PCNA, respectively) and in sera levels of angiopoietin-2 (Ang-2) end endoglin (sCD105) (using ELISA).
Results
All variables were higher in active MM patients compared to both healthy subjects and responders to conventional treatment (p<0.001 in all cases). Moreover, in active MM patients, MCD correlated positively with PCNA expression (r=0.490), Ang-2 (r=0.554) and sCD105 (r=0.566) levels (p<0.001 for all cases).
Conclusion
MCs enhance angiogenesis and probably through this procedure they also induce proliferation of plasma cells. Although the correlation seems to be rather indirect, MCs are major participants in MM progression and therefore could be considered possible targets for therapeutic interventions.
Session topic: E-poster
Keyword(s): Mast cell, Myeloma, Proliferation
Type: Publication Only
Background
Mast cells (MCs) are inflammatory cells that participate actively in multiple myeloma (MM) progression. They mainly enhance angiogenesis through production of various pro-angiogenic molecules, whereas they may also participate per se in the vascular plexus.
Aims
The aim of the study is to explore whether MCs participate in other aspects of MM progression, such as proliferation of plasma cells.
Methods
We studied 57 newly diagnosed patients with active MM, 26 of them in at least partial remission after receiving bortezomib-containing regimens, and 20 age and sex-matched healthy controls. We studied in bone marrow MCs density (MCD) and plasma cells’ proliferation rate (using immunohistochemical expression of tryptase and PCNA, respectively) and in sera levels of angiopoietin-2 (Ang-2) end endoglin (sCD105) (using ELISA).
Results
All variables were higher in active MM patients compared to both healthy subjects and responders to conventional treatment (p<0.001 in all cases). Moreover, in active MM patients, MCD correlated positively with PCNA expression (r=0.490), Ang-2 (r=0.554) and sCD105 (r=0.566) levels (p<0.001 for all cases).
Conclusion
MCs enhance angiogenesis and probably through this procedure they also induce proliferation of plasma cells. Although the correlation seems to be rather indirect, MCs are major participants in MM progression and therefore could be considered possible targets for therapeutic interventions.
Session topic: E-poster
Keyword(s): Mast cell, Myeloma, Proliferation
Abstract: PB1948
Type: Publication Only
Background
Mast cells (MCs) are inflammatory cells that participate actively in multiple myeloma (MM) progression. They mainly enhance angiogenesis through production of various pro-angiogenic molecules, whereas they may also participate per se in the vascular plexus.
Aims
The aim of the study is to explore whether MCs participate in other aspects of MM progression, such as proliferation of plasma cells.
Methods
We studied 57 newly diagnosed patients with active MM, 26 of them in at least partial remission after receiving bortezomib-containing regimens, and 20 age and sex-matched healthy controls. We studied in bone marrow MCs density (MCD) and plasma cells’ proliferation rate (using immunohistochemical expression of tryptase and PCNA, respectively) and in sera levels of angiopoietin-2 (Ang-2) end endoglin (sCD105) (using ELISA).
Results
All variables were higher in active MM patients compared to both healthy subjects and responders to conventional treatment (p<0.001 in all cases). Moreover, in active MM patients, MCD correlated positively with PCNA expression (r=0.490), Ang-2 (r=0.554) and sCD105 (r=0.566) levels (p<0.001 for all cases).
Conclusion
MCs enhance angiogenesis and probably through this procedure they also induce proliferation of plasma cells. Although the correlation seems to be rather indirect, MCs are major participants in MM progression and therefore could be considered possible targets for therapeutic interventions.
Session topic: E-poster
Keyword(s): Mast cell, Myeloma, Proliferation
Type: Publication Only
Background
Mast cells (MCs) are inflammatory cells that participate actively in multiple myeloma (MM) progression. They mainly enhance angiogenesis through production of various pro-angiogenic molecules, whereas they may also participate per se in the vascular plexus.
Aims
The aim of the study is to explore whether MCs participate in other aspects of MM progression, such as proliferation of plasma cells.
Methods
We studied 57 newly diagnosed patients with active MM, 26 of them in at least partial remission after receiving bortezomib-containing regimens, and 20 age and sex-matched healthy controls. We studied in bone marrow MCs density (MCD) and plasma cells’ proliferation rate (using immunohistochemical expression of tryptase and PCNA, respectively) and in sera levels of angiopoietin-2 (Ang-2) end endoglin (sCD105) (using ELISA).
Results
All variables were higher in active MM patients compared to both healthy subjects and responders to conventional treatment (p<0.001 in all cases). Moreover, in active MM patients, MCD correlated positively with PCNA expression (r=0.490), Ang-2 (r=0.554) and sCD105 (r=0.566) levels (p<0.001 for all cases).
Conclusion
MCs enhance angiogenesis and probably through this procedure they also induce proliferation of plasma cells. Although the correlation seems to be rather indirect, MCs are major participants in MM progression and therefore could be considered possible targets for therapeutic interventions.
Session topic: E-poster
Keyword(s): Mast cell, Myeloma, Proliferation
{{ help_message }}
{{filter}}